C-00001315
Braunschweig, Ira
The present invention outlines the framework, composition of a chimeric antigen receptor (CAR) targeting the CD25 for the treatment of adult T-cell leukemia and Lymphoma. The patent outlines method or composition of the CD25 CAR construct, which consists of the scFv fragment of the IL-2R alpha subunit, followed by the hinge and transmembrane region of CD8 molecule, followed by cytoplasmic region of CD28 and 4-1BB, and the cytoplasmic component of the TCR molecule. The entire nucleic acid fragment containing the above will be cloned in lentiviral backbone MSGV (mouse stem cell virus-based splice-gag vector) for its expression in the patient derived T-cell. The resulting CAR-T cells will target CD25 expressing leukemic cells in ATLL patients for its destruction reducing disease burden.
CART, CAR-T cells, T cells, chimeric receptor, CD25, IL2R
Patent Number / Application Number: PCT/US2020/048574
C-00000921
Levy, Matthew
The present invention is an aptamer (RNA) based antigen (vaccine molecule) delivery to antigen presenting cells, namely dendritic cells for the purpose of eliciting a strong T-cell mediated immune response. The patent outlines sequences and composition of such ribonucleotide aptamer for its conjugation with antigen. The specificity of the aptamer determines the molecule for delivery to the dendritic cells. Use of small oligonucleotide aptamers is an efficient approach as it avoids eliciting any immunogenicity, unlike antibody-based antigen delivery mechanism.
vaccine, antigen delivery, T cell, activation, dendrictic cells, aptamer
Patent Number / Application Number: 9688991
C-00001170
Kurland, Irwin J.
The present invention is the use of Directed Isotopic Positional Derivatization (DIPD) approach that utilizes 13C and/or 15N derivatization reagents to label compounds for Liquid Chromatography-Mass Spectroscopy (LC/MS) identification and quantitation. The patent outlines method of creating a 13C and/or 15N labeled DIPD reagent standards for LC/MS. It also outlines method for use of these reagents in metabolomic/lipidomic profiling of compounds in biological sample.
metabolomics, lipidomics, metabolic profiling, Directed Isotopic Positional Derivatization, DIPD, LC, MS, liquid chromatography, mass spectroscopy
Patent Number / Application Number: 10914741
C-00001270
Almo, Steve
The proposed technology is based on the discovery of the chemical identity of the product, ddhCTP, resulting from the reaction catalyzed by the enzyme, Viperin. The study also further uncovered for the first time the mechanism of antiviral action of the gene viperin. It plays role in uptake of ddhCTP that causes premature chain termination catalyzed by RNA-dependent RNA polymerase in viruses. Discovery of ddhCTP, sets the stage of developing small molecule analogues for use as therapeutics in inducing effective antiviral response against broad spectrum of viruses, including DNA and RNA viruses.
Broad spectrum, antiviral, small molecule, viruses
Patent Number / Application Number: 16/640,845
C-00001280
Magee, Mitch
The patent outlines a panel of tubeculosis (TB) biomarkers and method of use of these biomarkers in diagnosis of tuberculosis infection in humans using immunoassays performed on body fluids.
TB, tuberculosis, biomarkers, immunoassay
Patent Number / Application Number: 16/204,674
MTZ0009US5
GERTLER, Frank B.
The patent outlines methods to identify the possibility of whether a tumor is likely to metastasize or have undergone metastasis using gene expression analysis of sets of marker genes that are implicated to be involved in the process. It also outlines method to distinguish if metastasis is likely to happen or have occurred via lymph nodes using expression levels of sets of marker genes. It further outlines its use as screening tool to identify compounds with anti-metastatic properties by measuring the expression levels of these genes as endpoint assay, determining treatment type and its outcome and prognosis of cancer.
metastatic cancer, cancer diagnostic, gene expression
Patent Number / Application Number: 9926601
C-00001015
Garfein, Evan Stuart
The lead inventors have developed an intramedullary rigid fixation method of sternal closure. The process is accomplished using two components: (a) the sternal cutting guide for midline osteotomy to produce symmetrical sternal halves and (b) the fixation system to reduce and stabilize the sternal halves. The guide helps to produce accurate midline osteotomies minimizing sternal asymmetry. The components of the fixation system, which include, shims, ties, and brackets, help to ensure proper alignment and reduction of the sternal halves, inherent stability, and increased healing surface area. These provide an extremely low-profile implant, which affords anatomic reduction, thereby promoting faster healing and reducing postoperative complications. The proposed invention has the potential to substantially reduce mortality and morbidity associated with midline sternotomies.
sternal closure system, midline osteotomy, sternotomy
Patent Number / Application Number: 10179011
C-00001348
Bouhassira, Eric E
The invention disclosed is a regenerative cell therapy for treating different forms (hereditary, congenital, acquired or immune-mediated) of the disorder Thrombotic Thrombocytopenic Purpura (TTP). It involves isolation and culture of progenitor stem cell and its genetic modification to express a fusion protein having lipid anchor domain and the enzymatically active region of ADAMTS13 protein. Selecting these transduced cells and differentiating them into RBCs and expanding them in sufficient number for transfusing the cells back to the recipient subject having the disease. The goal here is that, the genetically engineered RBCs, with the active ADAMTS13 fragment will cleave the VWR factor, thereby correcting the cause of the disease at the molecular level. The patent outlines the composition, sequence of the chimeric fusion protein to be engineered into the progenitor cells. It also outlines method of treating the TTP using those genetically modified progenitor cells.
ADAMST13, Von Willebrand factor, fusion protein, cell therpay, stem cell, genetic engineering
Patent Filed
C-00001328
Reyes-Gil, Morayma
The invention is an image analysis software program that implements artificial intelligence systems architecture for interpretation, training and streamlining ways to identify neutrophil extracellular traps (NET). The current patent outlines a method of implementing such algorithm to a computable system associated with existing automated imaging and/or analysis system. It also outlines method for use of such an integrated system for the purpose of identifying and scoring a ratio of NETs to that of other white blood cells present in peripheral blood smear obtained from a biological sample.
image analysis, blood smear, neutrophil extracellular traps, AI, artifical intelligence, software, algorithm
Patent Filed
C-00000798
Loudig, Olivier
The current technology is unique in that it allows simultaneous extraction of both, RNA and DNA from fixed or unfixed biological samples. Fixed samples include both formaldehyde and paraffin. Among RNA species it allows extraction of low molecular weight microRNAs as well. The patent outlines stepwise method for extraction of RNA or DNA from biological samples. It also describes potential use of the method for use as a kit.
RNA, DNA, extraction, nucleic acid extraction, kit, mlecular biology kit, fixed samples
Patent Number / Application Number: 9309559
C-00001045
Levy, Matthew
The patent outlines the method of identifying a structure switching aptamer for a predetermined target without the need for further modification. The predetermined target can be a protein, a peptide, a small organic molecule or a cell.
aptamers, beacons, molecular biology
Patent Number / Application Number: 10144926
C-00001241
Frenette, Paul
The patent outlines a method of long-term culture of MSC in vitro without loss of vitality and property to support HSC growth. This is achieved through overexpression of factors Klf4, Ostf1, Xbp1, Irf3, and Irf7 together or in various combination through lentiviral transduction. Ability to maintain revitalized MSCs in long-term culture also provides a method to co-culture HSC. The latter can then be expanded to sufficient numbers outside the body for its reintroduction to the patient bone marrow for engraftment under clinical condition to correct a diseases condition.
engrafement, allogenic, HSC, hematopoetic stem cells, mesenchymal stem cells, MSC
Patent Number / Application Number: PCT/US18/36408
C-00001130
Almo, Steve
The patent is based on the discovery of four protein-protein interactions, which are: TNFR-1B and ICOS-L, TNFR-1B and MadCAM-1, TNFR-1B and ISLR2, and B7-1 and ISLR2. These interactions are vital due to the central role played by TNFR-1B and these binding partners in modulating immunity. Identification of these novel interactions provide for the first time an opportunity to screen compounds based on its ability to modulate these signaling modalities in health and disease related to immunity. This patent specifically discloses possible TNFR-1B mutants that can be screened or isolated based on its ability to regulate these binding interactions. It also outlines method of using these mutants (as fusion protein, soluble protein) for its use as therapeutics in human autoimmune disorder. The patent also outlines method of screening compounds (small molecules, antibodies, antibody fragments, peptide fragments) capable of disrupting these binding interactions for use as potential therapeutics against several human disorders resulting from autoimmunity.
TNFR-1B, ICOS-L, MadCAM-1, ISLR2, B7-1, screening, immunity, autoimmunity, bispecific antibody, fusion protein, peptide fragment
Patent Number / Application Number: 2018/0273604, 10717776
C-00000809
Chandran, Kartik
The patent outlines method for treating or preventing filovirus (Ebolavirus, Marburgvirus) infection in patient using any agent that inhibits the activity of one or several factors, which includes NPCI, VPS11, VPS16, VPS18, VPS33A, VPS39, VPS41, BLOC1S1, BLOC1S2, GNPTAB, PIKFYVE, ARHGAP23. The patent also discloses method for screening compounds for its use as anti-viral candidate against filovirus, based on whether the candidate has the ability to target and inhibit one or more of these factors outlined above. It outlines use of NPCI expressing cells for use as cell-based screening to identify agents that targets NPCI activity.
Filovirus infection, Ebola, Marburg, anti-viral,
Patent Number / Application Number: 9234885
C-00000681
Brenowitz, Michael D
A method for structural mapping a macromolecule in an aqueous solution
mapping, structure, macromolecule
Patent Number / Application Number: 9279814
C-00000977
LoPachin, Richard
The proposed invention addresses the need for improved methods and compositions for treating or preventing hepatotoxicity. It only targets hepatoxicity resulting from oxidative cellular damage by electrophilic metabolites of an administered therapeutic agent. The patent outlines formulae, composition of small molecules and method of use of such molecules in treating hepatoxicity. The method outlines use of these compounds either before/after/along with the use of therapeutic agent and its possible administration orally or non-oral manner.
cellular stress, oxidative stress, electrophiles, ROS, free radicals, cytotoxicity, cell damage, tissue damage
Patent Number / Application Number: 10104882
C-00001075
Shafritz, David Yovchev, Mladen I.
The underlying technology is a method to correct a liver disease through transplantation and repopulation of the diseased liver with genetically corrected and engineered liver cells. The patent outlines method for genetically modifying liver cells (derived from a subject/donor/cell line) with lentivirus transduced gene that expresses the Yapp-ERT2 fusion protein. Yap is growth control gene, while ERT2 makes it an inducible expression system by administration of Tamoxifen. Following genetic modification, the liver cells are to be transplanted into the recipient liver. To allow repopulation and expansion of cells the subject is to be administered Tamoxifen. The current approach has the potential to cure metabolic diseases due to genetic defects of the liver, and treat other end stage liver diseases.
organ transplant, liver transplant, cellular therapy, regeneration
Patent Number / Application Number: 15/510,915
C-00001359
Mahoney, Jeannette Rose
The invention is a mobile application to quantify the visual-somatosensory integration scores and its outcome on the cognitive and motor function of an older subject in a clinical setting. The application is based on the previous observation of a strong association between multisensory integration and balanced gait in a subject, such that one with low levels of integration demonstrated slow gait speed, shorter strides and at increased risk for fall. The mobile app is specifically useful for those older subjects who cannot travel to the test site (the institution) due to health conditions but can perform the test remotely in a clinical setting. The patent outlines the system (mobile device, computer) and method of performing the test using the application.
motor function, adult, fall, gait
Patent Number / Application Number: 17/038,974
C-00001334
Almo, Steve
MK production is a rate limiting step in bacterial respiratory chain and is thus crucial for its survival and propagation. The underlying foundation of this technology is the discovery of a non-canonical pathway of MK production in certain species of bacteria. Its identification led to targeting of a key enzyme (MqnE) in the pathway using a novel compound called, 2F-DHC to inhibit MK production, thereby providing an effective antibacterial therapy. The patent outlines structure, composition of the compounds and its method of use as a narrow spectrum antibiotic. A key aspect of this technology is that it can achieve effective elimination of certain species of disease-causing bacteria without compromising the beneficial gut microbiota. The treatment is potentially effective against H. pylori and Campylobacter jejuni infections. Of these H. polyri is a serious infection that afflicts a large global population and current antibiotics used to stop the infection are broad spectrum and with issues of antibiotic resistance.
Pylori infection, Campylobacter jejuni, Streptoccocus, Clostridium, Mycoplasma, Lactobacillus, Staphylococcus, Bifidobacterium, Rickettsia, Brusella bacterial infection, antibiotics, narrow spectrum, antibiotic resistance, gut, microbiota
Patent Filed
C-00000945
Schramm, Vern
The patent outlines structure, formulae and composition of compounds that can be used as inhibitors of the enzymes 5′-Methylthioadenosine phosphorylase (MTAP) and 5′-methylthioadenosine nucleosidase (MTAN). Both MTAP and MTAN catalyzes the conversion of methylthioadenosine (MTA) involved in the polyamine biosynthesis pathway, in purine salvage in mammals, and in the quorum sensing pathways in bacteria. MTA has been shown to induce apoptosis in dividing cancer cells, while having anti-apoptotic effect on dividing normal cells. These roles of MTAP and MTAN makes them an attractive target for inhibition for use an strategy for cancer therapy and in preventing anti-bacterial infection.
small molecule, inhibitor, cancer, bacterial infection, anti-bacterial
Patent Number / Application Number: 9493465
C-00001155
Mani, Sridhar
The patented technology is a method for diagnosing gut inflammation through identification of hyperswarming strain of bacteria from patient fecal sample. Unlike any other existing technology, it also outlines method for isolating and culturing pure strain of hyperswarmers from complex bacterial mix, present in a patient sample. The patent also provides method for its reintroduction into the host body for the purpose of treating or preventing various disorders related to gut dysfunction, intestinal inflammation. Finally, the technology proposes composition for treating intestinal inflammation using the isolated and purely cultured hyperswarmers.
Gut inflammation, micrbiome, probiotics, intestinal bowel syndrome, IBS, inflammatory bowel disease, IBD, Gut, microbiota
Patent Number / Application Number: 10857190
C-00001317
Jacobs, Jr., William R
The invention comprises engineered auxotrophic strain of M. tuberculosis and M. bovis BCG. Both the strains harbor double knockout of its endogenous genes. Of the two deleted genes one codes for an enzymes involved in the arginine and other for methionine biosynthetic pathways. The patent outlines the use of such attenuated strains for use as a vaccine in human subjects against to prevent or protect against tuberculosis infection. It also enumerates steps of use of such strain in use as diagnostics.
vaccine, tuberculosis, TB
Patent Number / Application Number: 17/268,789
C-00001180
Wang, Lihong
Reversibly switchable photoacoustic tomography (RS-PAT), a photoacoustic technique with enhanced sensitivity and resolution is outlined in the patent. RS-PAT utilizes a subtractive process for the formation of photoacoustic image of a region containing a plurality of switchable photoacoustic probes.
imaging, photoacoustic imaging, imaging device, probes
Patent Number / Application Number: 15/261,116
C-00000946
Achkar, Jacqueline Michelle
The patent outlines a method of detection of active M. tuberculosis or BCG infection in human samples (sera/plasma or whole blood) that is not drug resistant. The principle of the test involves identifying and quantifying the levels of IgG, IgA and IgM antibodies against three species of molecules of various sizes (MW) that are components of the M. tuberculosis and BCG membrane vesicle. The assay involves tagging these molecules, and using them as baits to identify and quantify cognate IgG, IgA and IgM molecules present in the sera/plasma. The patent also outlines method of treatment following diagnosis of tuberculosis or BCG.
tuberculosis, BCG, diagnostic, serological test
Patent Number / Application Number: 9841424
C-00000943
Peng, Qi
The patent outlines methods, apparatus and systems for determining the performance of one or more receiver coils of a magnetic resonance imaging (MRI) machine, or a hybrid-MRI machine, comprising a plurality of radiofrequency receiver coils.
MRI, imaging
Patent Number / Application Number: 9417307
C-00001030
Sibinga, Nicholas
This invention provides a method for treating restenosis in a vascular vessel of a mammalian subject. The patent outlines the use of an endovascular stent for use in angioplasty to treat atherosclerotic vessel. The stent is special in the sense that it can elute small inhibitor that inhibits the Wnt/beta-Catenin pathway. The stent is coated with polymer, where the polymer is adsorbed, or impregnated with the small molecule inhibitor, such that on position of the stent the inhibitor will be eluted for up to 150 days. The patent outlines the structure of the small molecule inhibitor of the Wnt/beta-Catenin pathway.
angioplasty, endovascular, coronoary, eluting stent, stent, Wnt pathway
Patent Number / Application Number: 10441687
C-00001406
Chandran, Kartik
A surrogate neutralization assay system for screening novel therapeutic, vaccine candidates and neutralizing antibodies against SARS-CoV-2. The team engineered the non-pathogenic, infectious, vesicular stomatitis virus (VSV) to express the spike S protein (S) and eGFP reporter to generate a recombinant surrogate virus, rVSV-SARS-2 S, that replicates to high titers. Using ex vivo studies, the team confirmed the surrogate viral entry into host cell to be ACE2- and TMPRSS2 protease-dependent. These properties make it an excellent model to study, design, and develop antivirals and vaccine candidates that inhibit the entry mechanism. The EGFP reporter further enables robust visualization and quantification of the assay. Using convalescent sera, the assay system was successfully validated for its the ability to detect neutralizing antibodies against spike protein reliably and efficiently. Novel mutant variants of the rVSV-SARS-2 S system allow robust scale up of viral production.
SARS-CoV-2, spike protein, neutralizing antibody, antiviral, vaccine
Patent Number / Application Number: PCT/US21/40460
C-00000442
Schramm, Vern
Sir2 (Sirt2), is a protein enzyme that requires NAD+ and acetylated protein for its deacetylation to form nicotinamide + o- acetyl-adp-ribose + a deacetylated-protein. The present invention is a discovery of a novel product of Sir2, called 2′-O-acetyl-ADP-ribose and its non-enzymatic conversion into 2′/3′-O-acetyl-ADP-ribose. The patent outlines method for assaying the presence of Sir2 or its activity. The assay components involve, NAD+, an acetylated peptide as substrate and the human/prokaryotic sample (source of Sir2). The presence of Sir2 activity is confirmed by chromatographic detection (HPLC) of 2′/3′-O-acetyl-ADP-ribose. Another method outlined involves use of radiolabeled NAD+ and detection of release radionucleotide as result of the enzymatic reaction.
Sir2, assay, detection
Patent Number / Application Number: 7432246
C-00001176
Deborah Cynamon, Jacob Cynamon, Golowa
The patent outlines a method of obtaining liver biopsy using a flexible sheathed system and needle. It also outlines the components required for the procedure for use a kit for obtaining liver biopsy.
liver, biopsy, device
Patent Number / Application Number: 10448931
C-00000973
Akabas, Myles
The patent outlines a method of screening agents that are potential inhibitors of the ENT type I transporters present in eukaryotic parasites using an assay system that is comprised of recombinant yeast. ENT transporter is a transmembrane transporter crucial for growth and survival of these parasites by allowing influx of purines nucleotides for anabolic synthetic process. Blocking these transporter leads to blocking of purine uptake that leads to killing of these parasites. The recombinant yeast was engineered to express heterologous ENT transporter as the sole transporter of purine nucleotides by replacing it endogenous transporters. The assay consists of the recombinant yeast cultured in a medium containing cytotoxic nucleotide in presence of an agent that it is to be tested/screened. The idea is that if an agent is inhibitor of the ENT transporter it will allow growth of the yeast even in presence of toxic nucleotide, if not the active transporter will uptake the cytotoxic nucleotide and kill the recombinant yeast.
parasitic disease, ENT, inhibitors, anti-parasitic,
Patent Number / Application Number: 10648012
C-00001087
Scharff, Matthew D
Somatic hypermutation or SHM, is an in vivo process by which immunoglobulin forming cells produces the vast repertoire of antibodies against its cognate antigens. Recapitulation of the same process in vitro within mammalian cell culture system is of great significance as it helps to produce diverse antibodies for therapeutic usage in the culture dish. The patent outlines a method of inducing SHM in immunoglobulin cell line through expression of the TAT protein of HIV. The process involves introducing the Tat gene in the immunoglobulin producing cell line by either lentiviral or adenoviral means.
antibody, diversification, antibody generation
Patent Number / Application Number: 10308930
C-00001148.2
Chandran, Kartik
The patent outlines method to treat, prevent or reduce filovirus infection in a subject, which includes Ebola virus (Zaire or Sudan stains), Marburg virus, a Bundibugyo virus, a Sudan virus, a Ravn virus or a Lluvia virus. The method comprises use of dual specificity bispecific antibodies directed against the target NPC1 (or NPC2) and filovirus glycoprotein, GP. The patent further provides composition, amino acid and nucleotide sequences of fusion protein constructs for developing the above-mentioned bispecific antibodies. The invention employs the knowledge of monoclonal antibody against the NPCI and antibody against the filovirus glycoprotein (GP), to come up with dual specificity bispecific antibodies that recognizes both. Binding to the virus particle helps the antibody to be transported to the endosomal compartment where it in turns binds NPCI, thereby preventing the viral particles from directly interacting with NPCI receptor, which is crucial for its entry into the host cell.
Filovirus infection, Ebola, Marburg, anti-viral, bispecific antibody, antibody
Patent Number / Application Number: 11149080
C-00000888
Guha, Chandan
Radiation induced gastrointestinal syndrome (RIGS), is caused by radiation induced depletion of intestinal stem cells. Currently there are no cure or therapy to restore these cells and often leads to death. The patent outlines method for treating, reducing RIGS or offer protection, prevention against RIGS. The patent outlines use of cultured adipose tissue derived stromal cells (ADSC) or bone-marrow derived stromal cells (BDSC) or their respective cultured supernatant for use in the treatment against of RIGS. The therapy can be administered by infusion into the blood stream (after HLA matching) and is capable of providing therapeutic value even when administered up to 72 hours following the end of exposure.
Radiation, exposure, RIGS, Radiation induced gastrointestinal syndrome, cellular therapy
Patent Number / Application Number: 9782441
C-00000753
Levy, Matthew
Targeted drug delivery to minimize off target effects while increasing on-site targeted effect.
aptamers, beacons, molecular, drug delivery
Patent Number / Application Number: 9540412
C-00000891
Stanley, Evan R
The invention involves discovery of a novel receptor for binding IL-34. This novel receptor is the protein tyrosine phosphatase receptor type zeta (PTP-ζ). Discovery of the PTP receptor allows ways to target IL-34 mediated inhibition or activation of cellular process related to pathophysiology or disorder. The current patent outlines a method of screening agents that disrupts the interaction between IL-34 and PTP-ζ and measuring a cellular response resulting from such inhibition on glioblastoma cells in brain.
IL-34, receptor, phosphatase
Patent Number / Application Number: 9671391
C-00000801
Dadachova, Ekaterina
The patent is a method for treating a patient with cancer or metastasis using attenuated bacteria (eg: Listeria monocytogenes) labelled with either 188Re or 32P or isotope. The invention combines the tumoricidal properties of bacteria and the ionizing radiation to selectively target and destroy cancer cells.
radiolabelled bacteria, cancer, metastasis, therapeutic bacteria, radiation therapy
Patent Number / Application Number: 10702614
C-00000826
Condeelis, John S.
The patent describes a method for treating breast cancer using anti-PTPN11 therapy, or anti-IL8 therapy, or anti-MYC or anti-TGFB therapy. The method of treatment is based on determining the gene expression signature of two distinct sets of marker genes within tumor samples, where set-I includes 45 genes and set-II with only 5 genes. Where upregulation of marker genes in set-I or downregulation of gene in set-II is associated with risk of metastasis, tumor invasion or tumor recurrence. Thus, it outlines a method of cancer treatment based on diagnosis of the risk for a tumor to metastasize, tumor invasion or tumor recurrence following a cancer treatment.
metastatic cancer, cancer diagnostic, tumor invasion, gene expresion, gene panel, metastsis, tumor recurrence, anti-PTPN11, ant-IL8, anti-MYC, anti-TGFB
Patent Number / Application Number: 9970057
C-00001286
Condeelis, John S.
The patent outlines a diagnostic method (a) for its use in identifying tumor samples that are positive for hematogenous metastasis, samples that have the ability to develop or undergo hematogenous metastasis (b) to determine a course of treatment for a person having metastatic tumor (c) to determine the efficacy of treatment and its prognosis (d) to screen compounds that inhibits, prevents or reduces tumor extravasation (e) and finally use it as a kit for use a diagnostic for all the above mentioned uses. The diagnostic method comprises of determining total TMEM score and Mena score for a tumor sample. A tumor sample is considered to be undergoing hematogenous metastasis if it has high-TMEM/high-Mena score. Alternatively, a tumor is considered to be devoid of metastasis or lack propensity to develop one, if it has low-TMEM/low-Mena score. The diagnosis utilizes immunological staining (on serial sections) of tumor samples for identification and imaging of tumor microenvironment of metastasis (TMEM), pan-Mena and MenaINV. Subsequent overlaying of images from serial sections, image analysis are used to derive TMEM score or Mena score using a mathematical formulae. A single TMEM unit is marked by presence of three closely juxtaposed components, which include a tumor cell (high for MenaINV or MenaCal), a CD68+ive macrophage (with high levels of Tie2, VEGF) and an CD31+ive endothelial cell (marked by low levels of VE-Cadherin and/or ZO-1). A total TMEM score is derived by counting all TMEMs within a field of view. The score is subsequently determined high or low based on set threshold cutoffs. A subsequent determination of Mena score is obtained either by directly measuring the MenaINV levels or by calculating MenaCal (by subtracting Mena11a expression levels from pan-Mena levels). High or low Mena score is determined based on pre-determined threshold cut offs.
metastatic cancer, cancer diagnostic,
Patent Filed
C-00001325
Almo, Steven
Dr. Almo’s research team at Einstein was able to develop an efficient, commercially viable method of biosynthetic production of biotin. It was possible due to discovery of a new class of biotin synthases (BioBs), called “type-II BioBs” (Figure 1A). This new enzyme was able to overcome kinetic hindrances posed by previously characterized BioBs (type-I BioBs). Type-II BioBs have a greater than 10-fold increase in enzymatic rate compared to type-I BioBs (Figure 1B). A significant enhancement in the property of the type-II BioBs is its structural stability, which allows it to be reused with longer turnover time compared to type-I BioBs. The latter are classified as “suicide enzymes” as it undergoes self-destruction in the turnover to biotin. These critical features of type-II BioBs accelerate a rate-limiting step in biotin biosynthesis and eliminates the bottleneck that prevented previous attempts at biosynthetic routes to biotin. Using nucleic acid engineering, introduction of these novel BioBs as a transgene cassette within a recombinant microorganism (bacteria, yeast) provides a platform technology for biosynthetic production of biotin for the first time. This method has immense potential to develop an efficient, scalable, highly cost effective and greener technology that is environmentally sustainable and more profitable.
biotin, production, biosynthesis
Patent Filed
C-00001094
Lai, Jonathan R
The patent outlines the structure, framework and composition of a bi-specific antibody capable of detecting, binding and neutralizing the pre-fusion core glycoprotein of two different species of Ebola virus at the same time. These species include Zaire and Sudan strain of Ebolavirus. The patent further outlines method of treatment that involves administering the bi-specific antibody to a subject.
ebola, sudan virus, zaire virus, filovirus, immunotherapy, monoclonal antibody
Patent Number / Application Number: 11135292
C-00001450
Verkhusha, Vladislav V
Dr. Verkhusha and his team, with years of expertise in engineering near-infrared fluorescent proteins (NIR-FPs), have developed multi-generation optogenetic systems. The latest is a next-generation system, called iLight, a highly sophisticated first-in-class single-component system. iLight is an engineering marvel derived from wildtype IsPadC phytochrome through random mutagenesis and high-throughput screening. iLight is capable of self-oligomerization upon incidence of light, thereby drastically reducing components. In contrast, the 1st-generation (1st-gen) multi-component system uses BphRs and its natural binding partner, PpsR2. The two approaches differ in their respective activation wavelengths; iLight is activated at 630 -680 nm (far-red zone) whereas BphRs-PpsR2 at 740 - 780 nm (near-infrared). iLight supersedes the rests in the degree and efficiency of the regulation achieved. In addition, a clear advantage of iLight is its enhanced compatibility with the AAV vector system, which makes it amenable for gene and CAR-T therapy within deep tissues of whole live animals. As a proof of concept, the team successfully tested iLight in vitro and in vivo in live mouse models to accurately turn on and off gene transcription in a tissue-specific manner.
near infrared, fluorescent protein, imaging, protein engineering
Patent Number / Application Number: PCT/US22/29781
C-00001169
Verkhusha, Vladislav V
Commonly used GFP-like fluorescent proteins (FPs) have a limited fluorescence range of a blue-green optical spectrum. Uses of other FPs in this spectrum also exhibit high background autofluorescence, weak emission, photobleaching and potential cytotoxicity in vivo. Dr. Verkhusha and his team were among the first to develop near-infrared fluorescent proteins (NIR FRs) from bacterial phytochrome photoreceptors, BphRs. These NIR FRs exploit endogenously available biliverdin in mammalian cell to absorb and emit light in the near-infrared range of 640 nm to 900 nm. Having longer wavelengths, the NIR FRs are far less damaging to the cells and provide low autofluorescence. Using protein engineering, the team developed a series of NIR FR variants, miRFPs and miRFPnanos that are monomeric and with improved spectral properties. The latest in this evolution of NIR FRs is miRFP670nano, a monomeric FR providing 30-fold higher brightness and 2.8-fold higher photostability than that of other NIR FRs variants. The team successfully tested miRFP670nano in vitro and in vivo mouse model as shown in the Figure. To this end, miRFP670nano is the smallest NIR FP currently available (17 kDa); 1.6-fold smaller than GFP-like FPs. Even more, NIR FPs do not require supplementation of exogenous chromophore. Additional applications include using NIR FPs simultaneously with GFP-like FPs as biosensors or protein tags in a crosstalk-free state.
near infrared protein, reporter protein, live imaging, marking cells, visulaization,
Patent Number / Application Number: 10442839
C-00001370
Verkhusha, Vladislav V
Commonly used GFP-like fluorescent proteins (FPs) have a limited fluorescence range of a blue-green optical spectrum. Uses of other FPs in this spectrum also exhibit high background autofluorescence, weak emission, photobleaching and potential cytotoxicity in vivo. Dr. Verkhusha and his team were among the first to develop near-infrared fluorescent proteins (NIR FRs) from bacterial phytochrome photoreceptors, BphRs. These NIR FRs exploit endogenously available biliverdin in mammalian cell to absorb and emit light in the near-infrared range of 640 nm to 900 nm. Having longer wavelengths, the NIR FRs are far less damaging to the cells and provide low autofluorescence. Using protein engineering, the team developed a series of NIR FR variants, miRFPs and miRFPnanos that are monomeric and with improved spectral properties. The latest in this evolution of NIR FRs is miRFP670nano, a monomeric FR providing 30-fold higher brightness and 2.8-fold higher photostability than that of other NIR FRs variants. The team successfully tested miRFP670nano in vitro and in vivo mouse model as shown in the Figure. To this end, miRFP670nano is the smallest NIR FP currently available (17 kDa); 1.6-fold smaller than GFP-like FPs. Even more, NIR FPs do not require supplementation of exogenous chromophore. Additional applications include using NIR FPs simultaneously with GFP-like FPs as biosensors or protein tags in a crosstalk-free state.
near infrared protein, reporter protein, live imaging, marking cells, visulaization,
Patent Number / Application Number: 17/115,223
C-00001428
Cai, Dongsheng
The invention is based on the observation that that neural stem cell (NSC) derived exosomes or their comprised piRNA repertoire serves to mount an adaptive immune response against viral infections. Using wildtype and pseudotyped SARS-CoV-2 viruses, the group demonstrated that murine NSCs contain large libraries of piRNAs against these viral genomes compared to non-neural mesenchymal stem cells. Using different human cell lines infected with pseudotyped SARS-CoV-2, the team further validated the antiviral potentials of these NSC exosomes. It showed that these NSC exosomes were also antiviral while their virus-induced versions had additional benefits against this virus. In summary, the present invention proposes a method of treating viral infections by administering NSC derived exosomes or specific combination of piRNAs present within them and delivered to subjects via exosomes/or other particles.
antiviral, HIV, SARS, piRNA, neural stem cells, exosomes
Patent Number / Application Number: PCT/US21/53580)
C-00001470
Kitsis, Rick
The gap between the annual worldwide demand for tissue allografts, organs and its supply are wide. This is largely due to inability to store, screen, match, and transport tissues along the path from the site of donor harvest, to tissue storage repository. As a result, a rapid loss of viability and function occurs and may become unsuitable for transplantation. A major cause of loss of viability is due to cell death, of which BAX mediated pathway is a critical component. The current patent outlines use of novel small molecule inhibitors that pharmacologically targets BAX activity effectively to prevent cell death. Proof-of-concept studies demonstrated that the BAX inhibitor solution could protect human kidneys. The patent further outlines the composition and method of use of such preservation and storage reagent in preventing loss of cell viability, biological activity, and/or tissue integrity for a wide range organs and tissues.
tissue, organ, preservation, solution, storage
Patent Filed
C-00000918
Gupta, Sanjeev
The patent comprises composition of a defined media for inducing differentiation of pluripotent stem cells into hepatocytes.
transdifferentiation, stem cells, media, composition, differentiation
Patent Number / Application Number: 10287552
C-00001044
Guha, Chandan
Radiation induced pulmonary syndrome (RIPS), is caused by radiation induced depletion of pulmonary stem cells. RIPS is characterized by loss of pulmonary function due to heightened inflammation and subsequent fibrosis that is scar tissue formation. Currently there are no cure or therapy to restore these cells and often leads to late mortality. The patent is a methods patent that outlines administering the stem cell specific growth factor, the human R-spondin1 (either as a purified recombinant protein or AAV mediated expression) to an individual who was exposed to harmful levels of radiation up to three months from the end of exposure to achieve therapeutic outcomes.
Stem cell therapy, radiation induced pulmonary sysndrome, cellular therapy, AAV
Patent Number / Application Number: 9439947
C-00000904
Jacobs, Jr., William R
The present patent outlines a method of developing a recombinant mycobacteriophage for delivering a gene of interest (eg: reporter gene) into a mycobacterium. The patent also outlines the use of such recombinant mycobacteriophage for the purpose of detecting presence of mycobacteria in a sample, and in screening of agents (antibiotics) that are effective against such mycobacteria namely Mycobacterium tuberculosis.
mycobacteriophage, mycobacteria, mycobacterium tuberculosis
Patent Number / Application Number: 9447449
C-00001106
Guha, Chandan
It is a methods patent that discloses ways to determine the levels and duration of exposure to radiation in a subject. Determination of the severity of exposure is crucial in making sound decision on treatment type. The same diagnosis can be used to monitor the efficacy of a treatment or disease prognosis. The diagnosis involves determining the levels of one or several micro-RNAs at the same time from the pool of listed miRNAs. The levels of the miRNAs are to be assayed from body fluids of subjects who underwent exposure and compared to controls to determine changes in levels.
Radiation, exposure, RIGS, Radiation induced gastrointestinal syndrome, radiation induced pulmonary sysndrome, RIPS, ARS
Patent Number / Application Number: 10801065
C-00001224
Goddard, Lee
The patent outlines the structure, function and method of use of a sterilizable device that is composed of electromagnetic transponders separated from one another by flexible spacer material enclosed within radiofrequency-transparent sterilizable tubing for target tracking during prostrate treatments.
device, tracking, surgery
Patent Number / Application Number: 16/482,724
C-00000942
Horwitz, Susan Band
The patent outlines a method of determining whether a prostrate sample is cancerous. The method involves using monoclonal antibody or antibody fragment directed against a given set of epitopes of the human βV-tubulin. The quantification of antibody or fragment binding helps to determine whether the sample is cancerous and if anti-cancer treatment is required.
antibody, fragment, tubulin, prostrate
Patent Number / Application Number: 9234899
C-00001083
Guha, Chandan
The patent outlines methods of detecting levels of radiation exposure in a subject using a kit. It describes the kit components and working of the kit for the purpose of detecting between 10 to 37 metabolites (from panel of 37) from the patient blood sample. The kit consists of a receptacle for loading patient blood sample, which feeds into mass spectrophotometer for determining the levels of a range of metabolites in the sample. The raw data from the spectrophotometer are interpreted by a computer with a machine-readable software for data analysis to quantify the metabolite level in order to determine accurate levels of radiation exposure and finally a unit to display the same.
Radiation, exposure, RIGS, radiation kit, blood sample, metabolites
Patent Number / Application Number: 11092591
C-00001481
Maslov, Alexander Y.
The technology is a method of accurately measuring and detecting genetic/epigenetic mutation profiles and DNA damage profiles in primary somatic cells and tissues. The invention has the potential for use as diagnostic kit for individual risk assessment by detecting exposure to biohazardous/carcinogenic substances, and testing mutagenicity of new and existing compound. Unlike various approaches currently employed in analysis of DNA strands for rare mutations the present approach uses base calling method that is far more accurate.
genetic, mutation, diagnostic, human, epigenetic, somatic, cells
Patent Filed
C-00001486
Ostrer, Harry
Screening women at risk of developing breast cancer is potentially lifesaving. Early detection and analysis of genetic profile of the cancer is crucial as it helps to determine the best individualized treatment plan for the patient with best clinical outcome. The present technology is a diagnostic test that accurately detects mutant variants in the DNA-double strand break repair pathway from the whole blood. The diagnostic test could be potential alternative to panel sequencing for its rapid and accurate detection abilities.
breast, cancer, diagnostic, mutant, DNA
Patent Filed
C-00001399
Karen Bonuck
The copyrighted material includes print and video materials on sleep education for kids. Sleep Health Education and Sleep Problems Education consist of flipcharts and printed materials addressing issues related to educating parents on matters of child sleep health and sleep problems, respectively. The Sleep Problems materials help inform parents of the potential need to seek medical attention for sleep problems.
pediatric, sleep problem, children, charts, questionaire
Copyright Protected
C-00001401
Karen Bonuck
Sleep Health Education and Sleep Problems Education consist of flipcharts and printed materials addressing issues related to educating parents on matters of child sleep health and sleep problems, respectively. The Sleep Problems materials help inform parents of the potential need to seek medical attention for sleep problems
pediatric, sleep problem, children
Copyright Protected
C-00001402
Karen Bonuck
Children's Sleep Habits Questionnaire is a set of questionnaires for use as a screening tool allowing for quick determination of potential sleep health problems in children. The questionnaire helps inform parents of the potential need to seek medical attention or parental counseling for particular sleep conditions that may be addressable through behavioral changes, although it should not be used to diagnose sleep problems.
pediatric, sleep problem, children
Copyright Protected
C-00001468
Verkhusha, Vladislav V.
Dr. Verkhusha, a pioneer in the field of engineering of fluorescent proteins and biosensors for super-resolution microscopy and deep-tissue imaging, and his group, have over the years discovered and developed near infra-red (NIR) and far-red (FR) fluorescent proteins with superior spectral properties. The latest addition are series of chimeric optogenic-Receptor Tyrosine Kinases (opto-cRTKs) that remains completely inactive in darkness but activated upon stimulation by FR light. This feature makes it them suited for all in vivo applications and manipulations. The optical part is made of photosensory core module (PCM) derived from Deinococcus radiodurans (DrBphP) bacterium. Using nucleic-acid engineering, the team engineered a novel chimeric receptor that targeted targeted DrBphP-PCM to to the cell surface by fusing to its N’-terminal the Igκ ER-signal peptide. Upon stimulation by FR light, thee extracellular PCM-DrBphP-PCM module underwent conformational changes that was transmitted via the EGFR transmembrane helices to the cytoplasmic RTK domains. The transmission of the optogenic signal from the cell exterior, resulted in their re-orientation and, trans-phosphorylation of the cytoplasmic RTK domains and activation of downstream signaling pathway
near infrared, far red, fluorescent protein, imaging, protein engineering
Patent Filed
C-00001397
Mani, Sridhar
The technology is based on the discovery that swarming bacteria are associated with intestinal inflammation. The proposed invention is a novel device for diagnosis of inflammatory bowel disease (IBD). The diagnostic comprises of a micro-patterned Polydimethylsiloxane biochip that helps to visually, identify and isolate swarming bacterial strain from patients with gut inflammation.
Gut inflammation, micrbiome, probiotics, intestinal bowel syndrome, IBS, inflammatory bowel disease, IBD, Gut, microbiota
Patent Filed
C-00000548
Dadachova, Ekaterina
The patent outlines method of producing engineered microorganisms (fungi or bacterium) that are capable of utilizing melanin as an alternative food/energy source when faced with lack or severe shortage of normal dietary nutrients. The patent outlines use of genetic engineering to introduce genes that produce enzymes involved in the melanin biosynthetic pathway, such that when they are exposed to radiation it will induce melanin production and buildup of melanin within the microorganism. An ultimate use of such microorganism would be to clean up radioactive contamination.
fungi, bacterium, microoragism, genetically engineered, radiation contamination, radioactive contamination.
Patent Number / Application Number: 8652827
C-00001271
DIAZ-GRIFFERO, Felipe
The patent provides a method for preventing or treating a flavivirus infection, a filovirus infection, a SARS-CoV-1 infection, a SARS-CoV-2 infection, or a MERS-CoV infection. The method is comprised of administering to a subject a therapeutically effective amount of a small molecule compound 6-deoxyglucose-diphyllin (DGP, formula-I) or its variation thereof (Formula-II). It is effective at low nM concentrations thereby reducing chances of adverse side effects.
Anti-viral, broad spectrum, small molecule, zika, drug, filovirus, SARS, flavivirus
Patent Filed
C-00001407
Almo, Steve
Herpes virus entry mediator (HVEM) is a tumor necrosis factor (TNF) receptor contributing to a broad range of immune functions involving diverse cell types. It interacts with both a TNF ligand, LIGHT, as well as the immunoglobulin (Ig) superfamily members BTLA and CD160. Assessing the functional impact of HVEM binding to specific ligands in different settings has been complicated by the multiple interactions of HVEM and HVEM binding partners. Additionally, HVEM’s failure to properly interact with BTLA has been implicated in B cell lymphomas and autoimmune disorders, while HVEM’s failure to properly interact with LIGHT has been implicated in viral diseases. As such, it would be beneficial to find a way to restore proper HVEM-BTLA or HVEM-LIGHT binding without affecting HVEM binding to its other partners to prevent off-target effects. Researchers at LJI and AECOM have found a way to do just that by creating HVEM muteins that are only able to bind one HVEM partner. Mouse data have shown that HVEM muteins able to bind only LIGHT cause mice to be less susceptible to Yersinia infection while HVEM muteins able to bind only BTLA cause mice to be less susceptible to liver inflammation.
muteins, TNF, inflammation, immunology, infection, viral
C-00000665
Mani, Sridhar
Unwanted and untimely activation of PXR activity play role in pathophysiological conditions like cancer, developing multi-drug resistance, negatively effecting bioavailability of drugs and its transport across blood-brain barrier. The invention proposes the use of ketoconazole derivatives as an inhibitor of PXR activity. The patent outlines method to produce these derivatives, its composition for the purpose of using it as a therapeutic agent in treatment of cancer and multidrug resistance. These are highly specific in their binding to PXR thereby reducing its off-target effects and toxicity, compared to existing PXR antagonist.
drug resistance, PXR, pregnane X receptor, small molecule, composition, structure
Patent Number / Application Number: 8669260
C-00001434
Chandran, Kartik
The invention is the discovery and development of human antibodies targeting Crimean-Congo Hemorghagic Fever Virus. The patent outlines the structure, composition of anti-CCHFV antibodies with neutralizing potency and protective efficacy against CCHFV. It also outlines methods of use in identification, isolation, generation of these antibodies.
monoclonal antibody, antibody, human, virus, antiviral
Patent Number / Application Number: 17/308,753
C-00001298
Lai, Jonathan R
The patent outlines sequence and composition of humanized monoclonal antibodies, antibody fragments against alphavirus (Chikugunya, Mayaro and O’nyong’nyong). These antibodies are directed against E2, p62, El, p62-El hybrid protein, or E1-E2 glycoprotein of Chikungunya virus. It also discloses nucleic acid sequence constructs for expression of the antibody or the fragments. The patent also comprises method for use of these antibodies in the treatment, prevention or inhibition of the alpha viruses mentioned above.
Chikungunya virus, Mayaro virus, O’nyong’nyong virus, antibody, monoclonal, antibody fragment, glycoprotein, virus, anti-viral
Patent Number / Application Number: PCT/US19/35828
C-00001426
Lai, Jonathan R
The outlined invention is a therapy to treat viral diseases caused by alphaviruses namely Chikungunya, Mayaro, and O’nyong’nyong viruses. The outlined therapy is comprised of monoclonal antibodies or antibody fragments against the alphavirus. The team successfully generated two lead monoclonal antibody candidates. The team demonstrated the efficacy and protective effect of these lead candidates using joint swelling and viremia mouse models of Chikungunya and Mayaro. Both antibody candidates were successful in significantly lowering viremia in vivo in organ and tissue while offering protection against virus induced arthritis in the mouse model. The patent outlines method, composition and sequence information of the monoclonal antibodies for use as therapeutics in the treatment of alphaviruses, namely Chikungunya, Mayaro, and O’nyong’nyong viruses.
alphaviruses, antiviral, monoclonal antibody, antibody fragment
Patent Number / Application Number: PCT/US21/50456
C-00001007
Lai, Jonathan R
The patent outlines the framework composition and sequence (heavy chain CDR1, CDR2, CDR3 and light chain CDR1, CDR2, CDR3) of a humanized monoclonal antibody against the Sudan strain of Ebola virus, which belongs to the family Filoviridae. The antibody is targeted against the glycoprotein and could be used in the treatment of subject infected with the virus. The patent also outlines method for using antibody or antigen binding fragment in the treatment of infected individual.
ebola, sudan virus, filovirus, immunotherapy, monoclonal antibody
Patent Number / Application Number: 10435461
C-00001357
Buelow, Hannes
The invention relates to discovery of antibodies or antibody fragments that are capable of binding to glycosaminoglycan (GAG) motif of glycoproteins present on the surface of cells. The repertoire of glycoproteins (glycotype) and its composition is unique to cell type and that varies with various disease condition. The patent outlines methods for use of these GAG motif binding antibodies or fragments to distinguish between cell types, for isolation and purification of specific cell types from a heterogenous mixture of cells and detecting a disease or disorder, and/or treating a disease or disorder based on a cellular glycotype.
GAG, glycoaminoglycans, antibodies, antibody fragments, cell isolation, cell purification, diagnosis
Patent Filed
C-00001277
Huffman, Derek
The present invention is based on the novel observation that using inhibitors to block IGFR-1 signaling improves or inhibits the progression of vital parameters of aging. The results from the study on mouse show that inhibiting IGFR-1 signaling using repurposed monoclonal antibodies, improve life span parameters, including longevity. The current patent outlines sequence and composition of antibody for use as inhibitor of IGFR-1 signaling. The patent also proposes method of preventing, improving or inhibiting healthspan parameters (that includes cardiac health or function, a motor function, a cognitive function, body fatness/leanness, muscle strength, exercise endurance, freedom from malignancy, inflammation) by administering the antibody inhibitor either alone or in combination with mTOR blocker.
IGFR-1, aging, logevity, life span, antibody, inhibitor
Patent Number / Application Number: 16/640,006; PCT/US18/48889
C-00000514
Condeelis, John S.
This patent outlines two method (a) the first for predicting the ability of a cancer to metastasize (b) and second is to identify motile metastatic cells from other tumor cells based on gene expression signature using high throughput gene expression study of breast cancer samples. The patent also describes method for obtaining and/or isolating motile cancer cells from a tissue using micro needles and its subsequent gene expression profiling to determine tumor metastasis.
gene expression, microneedle, breast cancer, mammary tissue, motile, metastasis, metastatic
Patent Number / Application Number: 8298756
C-00000804
Han, Weiguo
The patent outlines method of precisely introducing C-5 methylation at a predetermined cytosine residue/residues and quantification of the effects of such methylated cytosine residue/residues on the level of expression of the gene of interest. It uses standard molecular biology techniques to bring about the changes and quantification using quantitative PCR technique. The tools can be used as a laboratory molecular biology kit (tool/reagent) for introducing C-5 methylation of cytosine and its effect on gene expression.
DNA methylation, cytosine, kit, molecular biology kit
Patent Number / Application Number: 8993242
C-00000621
Condeelis, John S.
Mena is a cytoskeletal protein that plays important role in the metastasis of cancer cell because of its anti-capping role in actin filament organization. At the core, the invention relates the overexpression two splice variants of Mena, ++ and +++ isoforms and its association with metastatic breast cancer cells. The patent outlines method for diagnosis of presence of metastatic tumor in a subject, its prognosis, and outcome following a therapy. It uses the expression profile of the two variant isoforms of Mena, for ++ and +++ to determine the presence of metastatic cancer or cancer cell dissemination. However, unlike the parent patent it also proposes method for its use as a screening tool to identify therapeutics, namely biologics (ribozyme, RNAi molecule, antibody) or aptamers that are capable of inhibiting metastasis of a tumor in a subject by targeting the expression or activity of these isoforms. this patent drills down on the specifics of its use as a diagnostic kit for assaying Mena isoforms. One of the patent also outlines a PCR based detection kit that comprises of nucleic acid sequence for encoding +++ isoform and Mena11a, various PCR primer sets for detecting pan Mena, and specifically for Mena11a, ++ and +++ isoforms. It also outlines sequence compositions and variations for these nucleic acid sequences.
metastatic cancer, cancer diagnostic,
Patent Number / Application Number: 8603738, 9719142, 2126566
C-00000834
Condeelis, John S.
The patent outlines method of screening an agent (small molecule, organic molecule, antibody, ab-fragment, siRNA, miRNA) that is capable of inhibiting sarcoma or carcinoma cell invasion or metastasis. An agent is determined to be antimetastatic by its ability to bind to the growth factor receptor (listed) and Ptp1b and increase their association in presence of certain levels of MenaINV and Mena. Method also outlines quantification of the association between growth factor receptor and Ptb1a. Increase in association corresponds to the ability of the agent in inhibiting carcinoma or metastasis, while decrease in association is interpreted as its role as disruptor of the association.
breast cancer, drug screening, growth factor receptor
Patent Number / Application Number: 10928397
C-00001267
Condeelis, John S.
The patent outlines method of inhibiting, reducing metastasis induced by chemotherapy or as an advance measure to prevent induction of metastasis in a patient about to undergo neo-adjuvant chemotherapy or who recently underwent one. The method comprises of a series of steps, which includes (a) firstly, determining the presence of or scope of developing metastasis by studying a patient derived tumor sample who underwent or about to go for chemotherapy respectively. (b) The diagnosis comprises of determining total TMEM score and Mena score (MenaCal or MenaINV) for a tumor sample. A tumor sample is considered to be undergoing cancer cell dissemination if it has high-TMEM/high-Mena score. It also outlines the use of the scores as a basis for determining the probability of a tumor developing resistance to receptor tyrosine kinase therapy (RTK) (c) using the score to develop a course of treatment for patients undergoing metastasis or tumor invasion. In case of patients undergoing chemotherapy for the first time, the TMEM and Mena score calculated will be used as control for comparison against TMEM and Mena score obtained after chemotherapy to determine probability of developing metastasis. (d) Treatment includes inhibiting the activity of TMEM by targeting its individual components (e) The various treatment options includes, using Tie2 inhibitor, CSF1R inhibitor, a VEGFR inhibitor or agents that inhibits or reduces MenaINV expression. For patients about to undergo neoadjuvant chemotherapy, a treatment option could be a combination of a chemotherapeutic agent and one of the TMEM inhibitors (Tie2 inhibitor).
metastatic cancer, tumor invasion, dissemination, lung, breast
Patent Number / Application Number: 16/616,848
C-00001455
Tomer, Yaron
The invention outlines the use of Cepharanthine, natural plant-based alkaloid for use in the treatment of Autoimmune Thyroid Diseases (AITD) and type 1 diabetes (T1D). In a large subset of AITD & T1D patients the HLA molecule presenting self-antigens is HLA-DR3. Therefore, the strategy used was to block HLA-DR3 in order to prevent the presentation of self-antigens to T cells, thereby reversing the autoimmune disease. Through a high throughput screening and many validation platforms we have identified Cepharanthine, a natural plant alkaloid, to be a potent blocker of HLA-DR3.
Cepharanthine, alkaloid, autoimmune, thyroid, diabetes, T cells
Patent Filed
C-00001208
Condeelis, John S.
The invention is an imaging system a multiphoton or confocal microscope for intravital capture of image in a predetermined target tissue of a live animal. Intravital imaging acquisition is enabled through a window, a microfluidic intravital window placed strategically adjacent to the tissue under observation. A microfluidic intravital window comprises of (a) an intravital imaging window adapted for implantation adjacent to the target tissue of a live animal, (b) and a microfluidic fluid source and (c) delivery system physically integrated with the window for controlled delivery of chemical/drug to the target tissue via the window. The microfluidic fluid source and delivery system is self-contained and completely located on the inner surface of the intravital imaging window. The patent outlines method of capturing live image using such an image system. It also outlines method of use of such imaging system to monitor tumor cell movement, extravasation, tumor growth, tumor progression to metastases, and dynamics of cellular interaction.
diagnostics, imaging, itravital window, live imaging, microfluidcs, PDMB, drug delivery, metastases, mtastasis, tumor growth, extravasation
Patent Number / Application Number: 10117990
C-00001381
Hebert, Jean M.
This invention describes a method to engineer and transplant microglia cells as a vehicle for delivering widely dispersed biologics in adult brain. These biologics can be protein, or peptides or antibodies expressed from within the engineered and transplanted microglia. Other potentials include cell replacement therapies for neurodegenerative diseases or a vehicle for introducing new neurons.
drug delivery, cell therapy, microglia, delivery vehicle
Patent Number / Application Number: PCT/US21/26419
C-00001290
Santambrogio, Laura
The invention is the discovery of a previously uncharacterized metabolite called 3OH-Kynureamine of the Tryptophan breakdown pathway that is released by the lymphatic endothelial cells (LEC) upon stimulation by IFN. In addition, the group identified the enzyme responsible for its production and the receptor (aryl hydrocarbon receptor, AHR) that binds to 3OH-Kynureamine to transmit its intracellular signaling. It further demonstrated a potential role of 3OH-Kynureamine in immune tolerance and immune suppression by its effect on upregulation of the levels of TGF, IL-10, IKB gene expression. The patent outlines a method of treating an autoimmune condition or to prevent graft rejection by suppressing immunity through administering of therapeutically effective amount of either 3OH-Kynureamine or an agent that stimulates 3OH-Kynureamine production and secretion by the lymphatic endothelial cells.
immunosuppression, autoimmunity, T cell activity, dendritic cells, lymphatic endothelial cells, graft rejection, inflammation, immune tolerance
Patent Number / Application Number: 16/980,204
C-00001288
Zang, Xingxing
B7x (B7 homolog x, also known as B7-H4, B7S1, and VTCN1) was discovered by the inventor is an inhibitory immune checkpoint of great significance to human disease. B7x-Ig fusion protein inhibits T cell functions and promotes the conversion of conventional CD4-T cells into immunosuppressive regulatory T cells (Tregs). In proof of concept studies B7x-knockout mice are resistant to pulmonary infection with Streptococcus pneumoniae. In another model, mice overexpressing B7x in the B-cells are resistant to CD4 T cell- or CD8-T cell mediated type I diabetes. These results demonstrate that B7x fused to the human IgG-Fc fragment has a great potential to be utilized as a drug that targets T-cells for treating multiple autoimmune disease condition. The patent outlines the structure and sequence of human monoclonal bodies against the IgV domain of B7-H3. It also oulines the use of such mAbs for the treatment of cancer and infection.
immune checkpoint, B7x, antibody, monoclonal, human
Patent Number / Application Number: 17/294,560
C-00001043
Chandran, Kartik
The basis of the patent is the invention that the protein protocadherin-1 (PCDH1) expressed on the surface of the host pulmonary epithelial cells and macrophages is required for hantavirus entry and infection of host cells. Thus, preventing the entry would prevent infection and protection against hantavirus pulmonary syndrome (HPS). The patent outlines method of treating an infected patient or a subject at risk of exposure to infection by targeting the activity of the protein PCDH1. The method comprises use of an antibody (monoclonal) or antibody fragment that binds (extracellular domain) and inhibits the activity of PCDH1, thereby preventing entry of the virus, which includes Sin Nombre virus (SNV), Andes virus (ANDV), New York Virus and Black Creek Canal Virus.
Hantavirus, Sin Nombre virus, Andes virus, New York Virus, Black Creek Canal Virus
Patent Number / Application Number: 10105433
C-00001349
LEE, Kyuwan
The patent outlines a method of synthesizing/developing reduced metal nanoparticles. It also outlines method of modifying these nanoparticles with various entities (thiol, biotin, streptavidin, polyethylene glycol, an amine group, a carboxyl group, an alkyl group, a peptide, DNA, RNA, an antibody, or a combination thereof) or make them suitable/fit for various in vivo functional uses by tagging them with a dye, protein, nucleic acid and antibody like molecules.
nano particles, reducing metal,
Patent Filed
C-00001449.1
Verkhusha, Vladislav V
The invention outlines a new class of nanobodies that are allosterically unstable when not bound to its cognate intracellular antigen, and consequently degrade in mammalian cells, but become highly stabilized when bound. To enable optical imaging of these novel Nbs, they were genetically fuse with next generation, highly optimized near infrared-FP (NIR-FP), called miRFP670nano to form NIR-Nbs. miRFP670nano is immensely powerful fluorescent protein, given it is small size (17 kDa), higher brightness, faster maturation, and enhanced photostability. The final product of this fusion are highly sophisticated NIR-Nbs: that are highly specific, readily degradable when unbound, provides significantly high signal-to-noise ratio and allows deep tissue imaging at whole animal level with great resolution.
nanobody, near infrared, fluorescent protein
C-00001449.2
Verkhusha, Vladislav V.
Dr. Verkhusha, an expert in the field of engineering of fluorescent proteins and biosensors developed a new class of Nbs that are allosterically unstable when not bound to its cognate intracellular antigen, and consequently degrade in mammalian cells, but become highly stabilized when bound. To enable optical imaging of these novel Nbs, they were genetically fuse with next generation, highly optimized near infrared-FP (NIR-FP), called miRFP670nano to form NIR-Nbs. miRFP670nano is immensely powerful fluorescent protein, given it is small size (17 kDa), higher brightness, faster maturation, and enhanced photostability. The final product of this fusion are highly sophisticated NIR-Nbs: that are highly specific, readily degradable when unbound, provides significantly high signal-to-noise ratio and allows deep tissue imaging at whole animal level with great resolution.
nanobody, near infrared, fluorescent protein, imaging,
C-00000922
Schramm, Vern
The underlying invention is based on the discovery of a novel pathway of menaquinone synthesis in Helicobactor pylori. This nutrient is essential for growth and survival of H. pylori and is absent in humans and other human gut microbiota. This makes this pathway an ideal target for developing drugs. The patient comprises of formulae, composition of small molecules for the treatment of Helicobacter pylori infection in humans. The invention addresses the need for new compounds that selectively targets the enzyme HpMTAN in H. pylori to prevent menaquinone synthesis.
pylori infection, helicobactor pylori infection
Patent Number / Application Number: 11186575
C-00000817
Schramm, Vern
The invention provides means of treating infections caused by bacteria belonging to Pseudomonas aeruginosa, Pseudomonas syringae or Xanthomonas campestris. The patent outlines detailed structure, formulae and composition of small molecule inhibitors that target the enzyme 5′-methylthioinosine phosphorylase (MTIP), which plays a crucial role in quorum sensing pathway in these bacteria. Methods for treatment involves administering to an infected patient an optimal dose of MTIP inhibitor capable of inhibiting sub-growth. The invention is of considerable commercial interests given the role of P. aeruginosa in hospital related antibiotic resistant infections around the world.
bacterial infection, drug resistant bacteria,
Patent Number / Application Number: 9290501
C-00001314
Fiser, Andras
The patent outlines various possible mutants of the human PD-1 receptor and its possible use as a fusion polypeptide with an immunoglobulin molecule for use as therapeutics in the treatment of cancer or diagnosing a tumor.
cancer, PD-1, antibody
Patent Number / Application Number: 17/278,869
C-00000963
Steidl, Ulrich
The patent outlines method for diagnosing and treating a blood cancer or a myelodysplastic syndrome in a subject. The crux of the technology is based on the identification and characterizing of a previously unknown target gene, BX648577. Dr. Stedil and his team were the first to discover the gene and its protein product. Using genetic gain-of-function studies the team succesfully showed that over expression of the protein is involved in leukemic cell growth while it ablation inhibited it. The studies paved the way for targeting this gene or its protein product for the treatment of AML
diagnosis, cancer, AML, myelodysplastic syndrome
Patent Number / Application Number: 10941209
C-00001148.1
Chandran, Kartik
The patent outlines composition, sequence identity of bispecific antibodies and fusion protein constructs for use in the treatment or preventing infection in subjects at risk of exposure to the filovirus. The invention employs the knowledge of monoclonal antibody against the NPCI and antibody against the filovirus glycoprotein (GP), to come up with dual specificity bispecific antibodies that recognizes both. Binding to the virus particle helps the antibody to be transported to the endosomal compartment where it in turns binds NPCI, thereby preventing the viral particles from directly interacting with NPCI receptor, which is crucial for its entry into the host cell.
Filovirus infection, Ebola, Marburg, anti-viral, bispecific antibody, antibody
Patent Number / Application Number: 11149080
C-00001165
Schramm, Vern
Dr. Vern Schramm, an expert in enzyme transition state have developed potent selective small molecule inhibitors of DNA methyltransferase 1 (DNMT1) and their use as therapeutic agents against various cancers.
small molecule, inhibitor, cancer, DNMT1
Patent Number / Application Number: 17/466,790
C-00001316
Schramm, Vern
Dr. Vern Schramm, an expert in enzyme transition state have developed potent selective small molecule inhibitors of DNA methyltransferase 1 (DNMT1) and their use as therapeutic agents against various cancers.
small molecule, inhibitor, cancer, DNMT1
Patent Number / Application Number: 17/250,330
C-00000776
Wu, Peng
The standard azide-alkyne cycloaddition catalyzed by Cu is toxic which limits its usage in the living system. To bypass the problem the inventor has proposed the use of tris (triazolylmethyl) amine-based ligands for Cu. The patent outlines the detailed structure and composition of these ligands for use with CuSO4 for cycloaddition reaction. The reaction thus catalyzed using these ligands are safe and can be readily used for imaging biomolecules and living systems.
live imaging, imaging, biolmolecules, reagents
Patent Number / Application Number: 9809560
C-00001459
Kalpana, Ganjam
The present invention relates to, composition, and methods for treating and/or identifying an agent for treating HIV infection. The disclosed agents are effective in Eradication/Cure" strategy to eliminate latent reservoirs of HIV, antiviral therapy to inhibit drug resistant viruses, and also for use in combination with the current therapy as a novel anti-HIV-1 drug. The drug is unique in its dual activity that targets both viral-host protein-protein and viral-viral protein-RNA interactions. The drug targets the interaction between human HIV-integrase (IN) and INI1/SMARCB1 and/or the interaction between IN and trans-activation response element (TAR) RNA.
antiviral, virus, HIV,
Patent Filed
C-00000771
Riska, Paul
The patent outlines detailed composition of medium for culturing Clostridium difficile and also details the method for usage of the medium for detecting the presence of C. difficile in a sample (stool or otherwise) using the EIA assay. The medium, along with other reagents required for the assay can be packaged as a kit.
Clostridium difficile, detection, medium, culture, kit
Patent Number / Application Number: 8765399
C-00000768
LoPachin, Richard
The present patent outlines the structure, formulae and composition of small molecule compounds and method of using these compounds to treat human disorders caused due to oxidative stress. The patent also outlines formulae, composition for its application as a nutrient supplement or for use on skin as an anti-aging agent in treating wrinkle and relief against sunburns.
free radicals, electrophiles, ROS, cellular stress, free radical, aging, tissue damage, cytotoxicity, cell damage, anti-aging, aging
Patent Number / Application Number: 8835510
C-00001326
Zang, Xingxing
CEACAM1(CD66a) is an immune checkpoint protein that plays a role in cancer and immunity. The patent outlines structure, composition of novel monoclonal antibodies targeting CEACAM1 and block CEACAM1-mediated T cell suppression. The patent also discloses the use of such mAbs in the treatment of cancer and infection.
immune checkpoint, T cell, immune, monoclonal antibodies, antibody
Patent Number / Application Number: 17/309,738
C-00001292
Lai, Jonathan R
The patent outlines the structure, composition and sequence of human monoclonal antibody or fragment against the Mycobacterium tuberculosis arabinomannan. The patent further outlines the use of these antibody or antibody fragment for treatment, detection and diagnosis of active Mycobacterium tuberculosis arabinomannan infection within a human subject.
antibody, monoclonal antibody, antibody fragment, diagnostic, tuberculosis
Patent Number / Application Number: PCT/US19/27218
C-00001377
Leyh, Thomas
Major Depression, MD (a depressive episode lasting at least two weeks) is worldwide mental health problem that effects one-in-five individuals. MD is treated primarily with serotonin-reuptake and monoamine oxidase inhibitors (3), both of which act by restoring synaptic levels of serotonin. More than 40% of patients fail to respond when taking these antidepressants alone. Thus, preventing sulfotransferase (SULT) activity in a monoamine-oxidase inhibited background, under combination therapy can substantially enhance serotonin activity. The present invention outlines structure, composition of small molecule inhibitors of enzyme isoform SULT1A3. Given the strong preference of SULT1A3 over other human SULT isoforms for the sulfonation of catecholamines, makes this small molecule inhibitors a potentially promising drug candidate for use in combination with other catecholic drugs for treatment of MD.
depression, mental health, inhibitor, small molecule
Patent Number / Application Number: 17/299,733
C-00001164.1
Gavathiotis, Evripidis
Apoptosis or regulated cell death is part of normal development process; however, unwanted or premature cell death is undesirable and associated with a number of pathological outcomes. The present invention addresses the need for inhibition of BAX activation for therapeutic treatments and diagnostic purpose. The proposed technology discloses method, composition of producing synthetic Fab antibodies that are specific for N-terminal active site of monomeric BAX and prevents its binding to MOMP and oligomerization. The technology also outlines method for measuring BAX activity for use as diagnostics in monitoring cellular/tissue health, and/or for screening compounds capable of modulating BAX activity. In addition, it also proposes method for using it as therapeutics against BAX mediated apoptotic cell death.
BAX, inibitor, Fab, antibodies, apoptosis, cell death, method, composition, usage
Patent Number / Application Number: 10294294
C-00001454
Amor Coarasa, Alejandro
The invention comprises structure, composition of series of 18F-fluorinated fatty acids and its implication in using a metabolic tracers for imaging or assessing metabolic activity within cells. These compounds can serve as extremely useful, non-invasive, functional tracers for use with positron emission tomography for in-vivo measurement of metabolic activity other than glucose. These can be extremely useful application in detecting cancer, cardiovascular, brain metabolism and some neurodegenerative diseases conditions.
tracers, metabolic, imaging, fluorinated fatty acids
Patent Filed
C-00001213
Lai, Jonathan R
The underlying invention is a phage library displaying various mutant peptides (engineered) spanning the IgV domain of the PD-1. This led to the identification of mutant polypeptides that exhibits high affinity for both PD-L1 and PD-L2. The patent outlines sequence and composition of an engineered mutant PD-1 polypeptide that is capable of binding to either PD-L1 or both with high affinity and specificity. It also outlines composition of fusion protein where the engineered polypeptide is fused to human IgG1-Fc domain. Finally, it also outlines method for T-cell activation for use in the treatment of cancer (targeting tumor with increased expression of PD-L1 or both PD-L1 and PD-L2) and infection.
PD-1, PD-L1, PD-L2, bispecific, fusion protein
Patent Number / Application Number: PCT/US17/31681
C-00001128
Wagshul, Mark E.
The patent outlines the design and use of an actuator device that when mounted to an existing motion-sensitive MRI machine helps to construct elastogram (MRE) of soft tissues (human brain). The actuator proposed is a significant enhancement over current actuators in efficiently inducing motion in the brain without discomfort. The actuator is placed on skin overlying bone, such as cheekbone, skull, pelvic bone or spinal vertebrae. The method is used for diagnosis and/or prognosis of disease, such as cancer, hydrocephalus, Alzheimer's disease, epilepsy, multiple sclerosis, liver cirrhosis, or liver fibrosis.
MRE, Magnetic resonance elastogram, soft tisse, imaging, actuators, MRI
Patent Number / Application Number: 10694973
C-00001429
Tomer, Yaron
Cluster of differentiation 40 (CD40) plays a central role in the immune system and was shown to be a key susceptibility gene for several autoimmune diseases. Consequently, CD40 is an attractive therapeutic target for various autoimmune and related conditions. However, recent reports show that not all patients with autoimmune diseases benefit from CD40-targeted therapies. Currently no diagnostic method exists that can accurately stratify patients based on their predicted ability to respond to CD40-targeted therapy. Dr. Yaron Tomer and his team at Albert Einstein College of Medicine developed a precision diagnostic test that will help to tailor the anti-CD40 therapy to patient subsets who are most likely to benefit from it. The diagnostic consists of a simple genetic test performed on biological samples (peripheral blood, liquid biopsy, or buccal swab) to genotype single nucleotide polymorphisms (SNPs) at the CD40 locus (haplotyping).
CD40, precision diagnotic, personalized diagnostic,
Patent Filed
C-00001096
Levy, Matthew
The invention outlined is a method of making stabilized lipid-micelles using oligoribonucleotide-lipid conjugates. The inclusion of 2 – 60 ribonucleotide long oligos not only stabilizes the micelles but also provide a means of targeted drug or diagnostic (dyes) delivery in a programable manner. A portion of these oligonucleotides is present on the external surface of the micelles can bind protein or complementary oligonucleotides. Addition of the antisense oligos binds to the complementary oligonucleotides on the lipid micelles and make them unstable thereby triggering the release of its content in a programable manner. The current patent outlines methods for making this serum stabilized oligonucleotide-lipid conjugated micelles and also outlines its use in the delivery of hydrophobic drugs and dyes in vivo to target cells and tissues.
drug delivery, ddye delivery, micelles, lipd micelles,
Patent Number / Application Number: 10780051
C-00000940
Fisher, John
Ventricular epicardial lead implants or VT ablation are attractive procedures but possess a challenge due to concerns of coronary artery damage. The proposed invention is a device comprising of an epicardial pacing lead delivery sheath, the sheath comprising a lumen and comprising a Doppler blood-flow probe at the end of the delivery sheath. Signal from the Doppler blood-flow probe allow to determine the proximity of the end of the sheath to a blood vessel of a predetermined size or above. The current patent outlines method of placing epicardial lead implants or VT ablation in patient with arrythmia using the device outlined.
Doppler, epicardial lead placement, arrythmia
Patent Number / Application Number: 14/416,159, PCT/US15/60517
C-00000907
Lipton, Michael L.
The present invention enhances the current MRI technology by allowing detection and interpretation of pathology of brain at individual level, which otherwise would have remained undetectable. The invention consists of a software and device that provides quantitative analysis of MRI images to detect image abnormalities of an individual patient. The current patent outlines method of such quantitative assessment of volumetric images obtained from a patient for the purpose of diagnosis.
Imaging, MRI, image analsysis, software,
Patent Number / Application Number: 9245334
C-00000761
Zhou, Bin
A method of producing artery specific endothelial cells for use in cellular therapy in cardiovascular disease.
regenerative, cellular therpay, endothelial cell
Patent Number / Application Number: 9511097
C-00001228
Streamson C. Chua
The invention is an optogenetic device that uses blue light (visible) to influence the protein function within nerves to stimulate or induce a desired sensory or physiological outcome. In this case, the device uses blue light to induce or activate the function of channelrhodopsin2 (ChR2) (introduced into the target tissue or organ through AAV viral transduction) to trigger the stimulation of autonomic nerves involved in the glucose production in the liver. The patent outlines the use of AAV viral vector to introduce ChR2 protein expression within the autonomic nerve fibers within liver. The patent also outlines method of using the device to stimulate autonomic nerves fibers by activating the Chr2 protein for inducing hepatic glucose metabolism. This device and method are of therapeutic significance in individuals suffering from Type 2 diabetes
Optogenic device, AAV, gene therapy, viral vector
Patent Number / Application Number: 16/605,360
C-00000924
Levy, Matthew
The proposed invention is the discovery of a ribonucleic acid aptamers (RNA) that can bind to the transferrin receptor. The binding is non-competitive, such that it can bind to its cognate receptor even in presence of high concentration of transferrin. The patent outlines sequence and composition of these aptamers. It also outlines method of delivering an agent to the transferrin receptor in form nanoparticles, liposomes conjugated with the aptamer for use as therapeutics. Finally, the patent outline method of use of such aptamers in preventing infection by arenavirus that utilizes the transferring receptor for its host entry.
aptamer, transferrin receptor, arenavirus
Patent Number / Application Number: 9439973
C-00001221
LEVY, Matthew
The patented technology outlines a major improvement in method of developing ribonucleic acid aptamers with enhanced in vivo stability and diversity within its backbone. The technology provides allows to generate highly stabilized, backbone modified RNA aptamers that display enhanced chemical functionality. The resulting RNA aptamer is capable of selectively binding to a target in a tissue or cell surface, or protein of interest or small molecule.
aptamers, beacons, molecular biology, RNA
Patent Number / Application Number: 11008576
C-00001230
Casper, Diana (deceased)
The invention is a method of producing Acyl-Para-aminophenol derivatives in pure crystalline form. Unlike current methods that uses complicated, lengthy process where the end product is in oil form, the outlined approach is simple, rapid and produces crystalline form. The patent further outlines the structure and composition of newly synthesized novel compounds using the approach and their usage as therapeutics in the treatment of cancer.
production, chemical, cancer
Patent Number / Application Number: 17/308,507
C-00001160
Verkhusha, Vladislav V
Dr Verkhusha and his team, with years of expertise in working with near infrared fluorescent proteins (NIR-FPs) and its engineering has developed a first-in-class optogenetic system, with the ability to precisely control molecular interactions intracellularly using NIR-light. The system consists of two separate components, the NIR-FP called BphRs and its natural binding partner, PpsR2. Exposure to near-infrared light or its withdrawal induces either binding or dissociation of BphRs-PpsR2 respectively. Depending on different protein/peptide components tagged with BphRs and PpsR2 respectively, the association either turns ‘on’ or ‘off’ a desired molecular function. These function ranges from inducing subcellular translocation, protein-protein interaction, activating/inhibiting gene transcription/protein synthesis, and enzyme activation, in vivo within mammalian cells and deep tissues of live animal.
reporter, fluorescent molecule, near-infrared, protein tagging, cell fate, optogenetics
Patent Number / Application Number: 10968256
C-00001202
Gavathiotis, Evripidis
Apoptosis plays a critical role in embryonic development and tissue homeostasis. The dysregulation of apoptosis is pivotal to a number of high mortality human pathogenesis including cardiovascular diseases and neurodegenerative diseases. The pro-apoptotic Bcl-2-associated x-protein (BAX) is a central mediator of both necrosis and apoptosis. Therefore, inhibition of pro-apoptotic BAX impairs the cells' ability to initiate premature or unwanted cell death in terminally differentiated cells, including cardiomyocytes and neurons. The present invention address the unmet need for inhibitors of BAX, which can be used to treat the indications in which inhibition of premature or unwanted cell death is desirable. The invention provides novel Bax inhibitor compounds, and methods of using these compounds for treating conditions in which it is desirable to inhibit BAX, such as a cardiovascular disease, neurodegenerative disease or chemotherapyinduced cardiomyopathy.
small molecule, inhibitor, BAX, cardiovascular disease, neurodegeneration
Patent Filed
C-00001323
Gavathiotis, Evripidis
Ealy efficacy with current RAF inhibitors, melanoma patients with oncogenic mutBRAF signaling eventually relapsed after 6 – 12 months. Unlike, melanoma patients the initial success with these Raf inhibitors are very limited for colorectal and thyroid cancer with mutBRAF. The main reason for this ineffectiveness is due to lack of inhibition of the mut BRAF and wtBRAF in its dimerized form. The proposed technology overcomes this problem by being able to solve the co-crystal structure of mutBRAF bound to Ponatinib. These led to discovery of new class of compounds with ability to bind and inhibit dimerized mutBRAF or wtBRAF. Identification of these novel compounds and repurposing of already approved Ponatinib holds considerable promise as novel and effective therapeutics against cancer treatment.
melanoma, RAF, BRAF, inhibitor, Ponatinib, colorectal cancer, thyroid cancer, dimer, kinase inhibitor
Patent Filed
C-00001227
Mani, Sridhar
This IP is related to C951 (the parent). The IP covers the method, composition, formulation and structure of small molecules indole derivates that can stimulate PXR activity for the purpose of treating or preventing all disorders related to gut barrier dysfunction, intestinal or gut inflammation or leaky gut syndrome. Using a proprietary and patented screening platform (US2018-0185422A1, Int Ref# C-0000951) it proposes identification of potential lead candidates. The proposed class of compounds standouts from other currently known PXR agonists by its lack of toxicity. The lack of toxicity is due to its structure that closely mimics endogenous bacterial metabolite indole and its derivatives.
Gut inflammation, micrbiome, probiotics, intestinal bowel syndrome, IBS, inflammatory bowel disease, IBD, Gut, microbiota
Patent Number / Application Number: 16/478,653
C-00000914
Eugenin, Eliseo A
The patent outlines a method to treat human subjects either infected or exposed to HIV using P2Y1 inhibitors. The patent also includes specific inhibitor to be used for the treatment.
HIV, P2Y1 inhibitor, treatment
Patent Number / Application Number: 9540646
C-00001200
Steidl, Ulrich
PU.1 belongs to a class of ETS transcription factors whose abnormal levels or activities have been implicated in a number of human disease conditions. The present patent outlines the structure, composition of small molecule compounds capable of modulating PU.1 function by inhibiting it. These molecules have the potential for use in the treatment of a number of disease condition in human with ages at least 60 years and above.
hematologic cancer, bone cancer, inflammatory disease, autoimmune disorders, endotoxemia neurodegenerative disease, leukemia, acute myeloid leukemia, rheumatoid arthritis, contact dermatitis, asthma, inflammatory bowel disease, chronic inflammatory diseas
Patent Number / Application Number: 10774049
C-00000581
Melnick, Ari Matthew
The patent outlines structure, composition of small molecule inhibitors of BCL6 repression in mammalian cell. The inhibitors could have a potential role as small molecule therapeutics in the treatment of cancer.
BCL6, small molecule, inhibitor, mammalian cell
Patent Number / Application Number: 8338464
C-00001063
Casper, Lalezari
The patent outlines structure, formula of small molecule compound that is an acyl-para-aminophenol derivative. It also outlines detailed method for chemical synthesis of such compound and its potential use as therapeutics in the treatment of tumor of glioblastoma and lymphoma.
small molecule, acyl-para-aminophenol derivative, tumor, glioblastoma
Patent Number / Application Number: PCT/US19/59885
C-00001162
Burgos, Emmanuel
The patent outlines method that involves chemoenzymatic steps of producing S-Adenosyl-L-Methionine (SAM) and S- Adenosyl-L-Homocysteine (SAH) analogs. The patent also outlines method of use of these analogs as therapeutics to treat cancer by targeting the activity of the enzymes, methyltransferases.
SAM, SAH, analogs, small molecule, inhibitors, anti cancer, methyltransferases
Patent Filed
C-00001234
Burgos, Emmanuel
The patent outlines method for assaying the activity of enzymes present in a biological sample that catalyzes the transfer of methyl group from S-adenosyl-L-methionine (SAM, methyl donor) to other biomolecules. These enzymes whose activity are measured are DNA or RNA methyl transferases present in a biological sample and catalyzes the transfer of methyl group from SAM to form SAH (S-adenosyl-L-homocysteine) and a methylated biomolecule as products. The patent also outlines the use of the assay method in screening inhibitors of methyltransferases.
S-adenosyl-L-methionine, SAM, methyl transferases, SAH, S-adenosyl-L-homocysteine, assay, kit
Patent Filed
C-00001235
Cheng, Emily H.
The patent outlines composition, formula and structure of small molecules that targets the activity of Bcl2 family of protein to induce apoptosis. It also outlines method for use of such compounds in the treatment of proliferative disorders in human subjects including cancer, inflammation and autoimmunity.
pro-apoptotic, antiproliferatice, Bcl2, apoptosis, small molecule
Patent Number / Application Number: 11098021
C-00001164.2
Lai, Jonathan R
The patent discloses sequence and composition of synthetic fragment antigen binding (Fab) against the monomeric Bax protein. The antibody fragment targets the N-terminal activation site of Bax that interferes its interaction with binding partners and thus prevents its activation and inhibition of apoptosis. The patent also outlines methods for (a) treating pathological condition that requires therapeutic intervention against unwanted cell death, (b) to assay for detection and quantification of amount of monomeric Bax in a biological sample, (c) and also use the antibody fragment for use as screening tool to identify compounds or molecules capable of inhibiting Bax.
therapeutic, antibody fragment, Bax inhibitor, apoptosis
Patent Number / Application Number: 10294294
C-00000682
Melnick, Ari Matthew
The patent outlines composition of peptides to block the activity of BCL6 and discloses method for use of such peptides in the treatment of cancer, namely B-cell lymphoma. The peptides in addition also harbors TAT and fusogenic sequences directly linked to it. These peptides have a favorable pharmacokinetic and toxicity profile as evident from in vivo studies, which makes them an attractive candidate for cancer therapeutics. The peptide works by binding to the lateral groove of BCL6 that interferes its binding with its corepressors and hence its repression of DNA damage response pathway.
BCL6, lymphoma, peptide, inhibitor,
Patent Number / Application Number: 8791075
C-00001392
Schramm, Vern
Clostridium difficile is a Gram-positive spore forming bacterium and is the leading cause of health care associated infections in the United States. C. difficile infections (CDI) arise following treatment with broad-spectrum antibiotics that disrupt the normal gut microbiota, allowing C. difficile spores to proliferate and to populate the gut. Toxin release from C. difficile cells leads to an inflammatory infection of the colon and potentially fatal diarrhea. Current treatment options ineffective in re-establishing the healthy gut microbiota, and does not neutralize the cell killing toxins already present in the intestines of infected patients. Antibiotic resistance is also a problem, leading to recurrences of CDI in approximately 20% of patients. These problems highlight the urgency for new treatments. TcdA and TcdB bacterial toxins are the primary determinants of human colon disease pathogenesis mediated by C. difficile. TcdA and TcdB mediate host cytotoxicity by inactivating host Rho family GTPases through glucosylation. Therefore, inhibitors of the TcdA/TcdB glucosylation reaction are attractive candidates for therapeutic development. Using transition state analysis, Dr. Schramm’s team at Einstein identified transition state analogue inhibitors, isofagomine and noeuromycin. In initial proof of concept studies, mouse model of C. difficile infection successfully confirmed the therapeutic potential of isofagomine against CDI mortality. These two compounds represent first-generation analogues that show potential for use as therapeutics against C. difficile pathology and/or prevention of C. difficile infection
Cdiff, cdiff infection, isofagomine
Patent Number / Application Number: PCT/US21/31072)
C-00001265
Stanley, Richard E.
The invention outlines a novel target pathway for intervention to prevent loss of cognitive function in patients with Leukodystrophy with axonal spheroids and pigmented glia (ALSP) and other neurodegenerative diseases involving neuroinflammation. The target is the GM-CSF signaling pathway, where a dominant negative mutation in the CSF1R kinase domain is associated with loss of microglia, neuroinflammation. Using in vivo proof of concept studies the lab have shown that loss of single GM-CSF allele is able to prevent cognitive loss and normalizes microglia numbers.
Leukodystrophy, ALSP, neurodegenerative, GM-CSF
Patent Number / Application Number: 17/284,599
C-00000800
Steidl, Ulrich
Successful treatment against AML and myelodysplastic syndrome (MDS) is mired due to lack of ability to remove leukemic stem cells (LSC) that escape chemotherapy and results in relapse (50%) and death. The problem is further complicated due to lack of marker specific to LSC to allow its targeted elimination without affecting the normal HSCs. The invention solves the above problems through discovery and identification of a novel biomarker on LSC that enables targeted deletion to achieve a lasting cure in AML patients. The patent outlines method for use of the technology as diagnostic to identify IL8 overexpression (which includes detection of its message and/or protein levels). The patent also outlines method for prognosis of disease progression, remission following a treatment regimen. Finally, the patent also proposes method of treatment of AML, myelodysplastic syndrome by targeting the activity of IL8 using antibody alone or conjugated with cytotoxic agent (radioisotope, chemotherapeutics).
Leukemia, leukemic stem cell, cancer stem cell, stem cell, IL8, AML, myelodysplastic sysndrome, diagnostics
Patent Number / Application Number: 9873918
C-00001452
Gavathiotis, Evripidis
Mitofusins1 and 2 (MFN1/2) regulate the physiological process of mitcohondrial fusion and subsequently mitochondrial function and signaling. MFN1/2 are localized on the outer mitochondrial membrae and undergo conformational changes and oligomerizaion to enable tethering and subsequent fusion of mitochondria. The proposed technology discloses structure, composition of small molecules capable of inhibiting the protein MFN1/2 to inhibit mitochondrial fusion and also outlines method for it use in therapeutic purpose. Mitochondrial fusion/fission is a critical step in mitochondrial biogenesis, which when impaired leads to a number of disease condition. The current technology is a first-in-class approach for targeting the activity of MFN1/2 for inducing mitcohondrial fission, decreasing mitochondrial respiration, TCA metabolism, and inducing mitochondrial outer memebrane permiabilization for use as therapeutics. These small molecules were identified through structure guided drug design and in silico screening for their ability to induce conformational change in MFN1/2 and its inhibition.
small molecule, inhibitor, mitofusins, mitochondria
Patent Filed
C-00001249
Gavathiotis, Evripidis
The proposed technology discloses structure, composition of small molecules capable of activating the protein MFN2 to promote mitochondrial fusion and also outlines method for it use in therapeutic purpose. Mitochondrial fusion is a critical step in mitochondrial biogenesis, which when impaired leads to a number of disease condition. The current technology is a first-in-class approach for targeting the activity of MFN2 for promoting mitofusion for therapeutic purpose. These small molecules were identified through structure guided drug design and in silico screening for their ability to induce conformational change in MFN2 and its activation.
mitochondria, fusion, small molecule, peptides, drug, MFN2, mitofusion
Patent Number / Application Number: 16/643,986
C-00001453
Almo, Steve
Binding interaction between B7-1 protein with the neuronal cell surface p75 neurotrophin receptor (p75NTR) protein triggers loss of synaptic connections that leads to number of deleterious conditions including neuronal inflammation and axonal injury. The patent outlines method and composition for treatment of neurological diseases by inhibiting or blocking the interaction between B7.1 and p75NTR. It also describes its usage for identifying therapeutic agents useful for treatment of neurological diseases and conditions.
neurological diseases, neurodegeneration, neuro, neurological
Patent Number / Application Number: PCT/US22/25730
C-00001484
Mani, Sridhar
The proposed technology is a method for treating and/or preventing conditions associated with gut barrier dysfunction. The invention is based on the primary in vivo and ex vivo evidence that strongly implicated a role for pregnane X receptor (PXR) activity in regulating gut barrier integrity. The present invention is identification of a novel, non-toxic PXR targeted anti-inflammatory therapeutic for treating gastrointestinal inflammation and gut barrier dysfunction including Inflammatory Bowel Disease. The novel compound identified is omega-muricholic acid or its derivative that acts as ligand for PXR. The patent further outlines, structure, composition and method for use of such compound for treating gut barrier dysfunction.
Gut inflammation, intestinal bowel syndrome, IBS, inflammatory bowel disease, IBD, small molecule, PXR, metabolite mimicry
Patent Filed
C-00001352
Cheng,Haiying
62/958,427 (Provisional); 17/144,715 (Non-provisional//US): The patent outlines structure, formula and compositions of small molecule inhibitors of RICTOR signaling. The patent further outlines method for using these small molecule inhibitors for preventing or treating metastases, particularly brain metastases associated with lung cancer, and reducing resistance to molecularly targeted therapy such as EGFR therapy. The mechanism of action of the disclosed inhibitors involve reducing resistance to cancer treatment in patients, who has developed resistance against EGFR, MET or AKT inhibitor therapy.
cancer, resistace, EGFR, AKT, MET, lung metastasis, metastasis, small molecule, inhibitor, drug, targeted therapy, molecular therapy, NSCLC, non-small cell lung cancer
Patent Number / Application Number: 17/144,715
C-00001210
Frenette, Paul
A method for treating hematologic malignancies by targeting VCAM1 (Vascular cell adhesion molecule 1). Low levels of VCAM1 expression on the hematopoietic stem (HSC) and progenitor cells is crucial to avoid phagocytosis by macrophages. The group successfully demonstrated that leukemic cells use the overexpression of VCAM1 to evade engulfment by immune cells. The group proposes blocking VCAM1 activity in leukemic cells using antibody or antibody fragment for treating hematologic malignancies. In their proof of principle studies conducted on a mouse model of AML, the researchers showed that VCAM1 alone or in combination with chemotherapy is associated with promising therapeutic outcomes without any apparent adverse effects.
oncology, hematologic malignancies, myeloproliferative disease, leukemia,
Patent Number / Application Number: 17/061,219
C-00001414
Lai, Jonathan R
The patent outlines the composition and structure of a monoclonal antibody or its fragment against the Spike protein of SARS-CoV-2. The patent also outlines method of use of such antibody/fragment in detecting the presence of the virus within a biological sample, or its use as therapeutics in preventing, inhibiting or treating the SARS-CoV-2 infection in a human subject.
SARS-CoV-2, spike, antibody, antibody fragment, monoclonal, diagnostic, antiviral
Patent Number / Application Number: PCT/US21/43866
C-00000952
Herold, Betsy
The patent outlines method for reducing the extent of already acquired and latent herpes infection. The method involves systemic targeting of Akt to inhibit it using topical mode of administration. The patent proposes this method of treatment in subject’s with resistance to either acyclovir and/or valacyclovir.
herpes simplex virus-1, herpes simplex virus-2, cytomegalovirus, Epstein Barr virus, human herpesvirus-6, herpesvirus-7, Varicella zoster virus, Kaposi's sarcoma-associated herpesvirus
Patent Number / Application Number: 9333219
C-00001287
Herold, Betsy
The patent outlines composition, structure of small molecule compound for preventing, reducing and treating a viral infection in a subject using a cell-impermeable inhibitor of Akt, scramblase and/or phosphatidylserine. It provides the structure of the inhibitor and the cell impermeable moiety. Further it provides method of using these compounds to treat herplex simplex virus infection (HSV-1 or HSV-2) in subject that is either in state of latency or having neurological symptoms.
AKT, scramblase, phosphatidylserine, viral infection, Ebola, flavivirus, Herpes
Patent Number / Application Number: PCT/US18/062502
C-00001344
Guha, Chandan
The patent outlines a method of mitigating or treating liver disease induced/inflicted as a result of radiation therapy administered for treating a primary disease condition (liver cancer, liver tumor, gastrointestinal cancer). The patent outlines methods of treatment that includes administering three components, a thrombopoietin (TPO) mimetic (preferably RWJ-800088 or romiplostim) with simultaneous transplantation of liver cells (preferably liver sinusoidal endothelial cells, LSECs) and a protein factor (from stem cell growth and differentiation factors: GCSF, GMCSF, HGF, VEFG, angiopoietin, CXCR4 antagonist, Rspondin-1, FLT3, amphiregulin). Two additional optional components mentioned are hepatocytes and hepatocyte protein factor.
liver disease, engrafment, radiation induced injury, irradiation
Patent Number / Application Number: PCT/US20/14934
C-00001310
Condeelis, John S.
TMEM is a marker for tumor invasion or dissemination. However, the identification or scoring of physical locations of TMEM within the tumor sample in predicting future dissemination is limited without the information on TMEM activity. The current technology utilizes the MRI scanning to measure the permeability of blood vessels at a TMEM location. This combined with assaying the MenaINV expression levels of the invasive cancer cells within the TMEM helps to establish the activity status of TMEM. This method is particularly useful as a minimally invasive procedure for primary diagnosis of metastasis or tumor invasion. Once confirmed, it can be followed up by collecting patient biopsy sample to perform immunostaining to further confirm active TMEM status, using CD31, CD68 and MenaINV and pan-Mena staining (as outlined in patent# 8642277, C-724). The patent outlines the above methods for its use in determining a strategy for cancer treatment, its prognosis and predicting outcome of such treatment.
metastatic cancer, cancer diagnostic, MRI
Patent Number / Application Number: 16/972,798
C-00000784
Lai, Jonathan R
The present invention involves the discovery of a rare HIV-1 antibody, 2G12, which has high affinity for oligomannose N-glycans due to its unusual domain exchange architecture. The patent outlines composition, the DNA construct that harbors the sequence for expressing the 2G12 antibody scaffold (VL, CL, VH, CH) on the surface of bacteriophage, which also includes sequences of possible variations of codon in the VL/VH region. The patent also outlines method for using the construct to derive phage display library for use as a tool to screen high affinity but rare glycan binding antibodies. The invention is of great significance given the role of glycans in modifying surface protein and its role health and disease, and difficulties in developing immunogenic response against these sugar moieties.
glycans, antibody, phage display library, disease, cancer,
Patent Number / Application Number: 9360483
C-00001425
Guha, Chandan
The patent outlines a method of treating a tumor or a cancer in an individual. It comprises administering to the individual a dose of high beam radiation therapy (or any energy-based therapy) of varying strengths. The radiation therapy is to be followed by administering a dendritic cell activating molecule at least following a day after the therapy. The dendritic cell activating molecule can be any agonist that activates either a toll-like receptor, a NOD-like receptor, a RIG-1 or MDA-5 receptor, a C-type lectin receptor or an agonist of costimulatory molecule belonging to the list CD40, CD80, CD86 and OX40. These molecules are to be administered either alone or combination to induce dendritic cell maturation.
radiation therapy, dendritic cell, cancer, tumor
Patent Filed
C-00001384
Schuster, Victor L
The present filing highlights the composition, structure of the next generation PGT inhibitors that were built upon three scaffolds in collaboration with CROs.
small molecule, NSAID, Cox, prostaglandin, fever, pain
Patent Filed
C-00001157
Guha, Chandan
The patent outlines systems, devices and methods for treating cancer and metastasis using acoustic low energy immune priming therapy. The immune priming energy is selected from the group consisting of Irreversible Electroporation (IRE), Microwave, Low-Intensity Focused Ultrasound (LOFU), High-Intensity Focused Ultrasound (HIFU), Radiofrequency energy and cryotherapy. The immunotherapies selected, includes dendritic cell targeted therapy, effector T-cell targeting, immune checkpoint inhibition. The system is designed for scanning total tissue volume and is comprised of a processor, one or several ultrasound transducers for delivering ultrasound beams of defined intensity, a probe to monitor patient and a user interface capable of delivering tumor image with inputs and input treatment options. The other adjunct therapies include radiotherapy, chemotherapy (listed). The patent also outlines method for use of the system/device for increasing efficiency of chemotherapy, treating a chemotherapy resistant tumor, inhibiting metastasis of a tumor in a subject, and reducing effective dose of a chemotherapy for treating a cancer, or sensitizing a tumor to an amount of anticancer therapy.
Ultrasound, devices, system, cancer, metastasis, immunotherpay, chemotherapy
Patent Number / Application Number: 17/191,497
C-00000724
Condeelis, John S.
The patent outlines method for detecting CD31+ive endothelial cell, a CD68+ ive macrophage, and an invasive tumor cell expressing high levels of +++ and/or ++ isoforms of Mena, which are in direct contact with each other. Obtaining a total count of such occurrence throughout the tumor sample to determine (a) the ability of tumor cells to undergo hematogenous metastasis (b) or to determine course of treatment and monitor disease progression. The method proposes use of immunological means (antibody/antibody fragment/peptide/aptamer) to identify these components. The patent also outlines use of the above diagnostic method for use as a kit, where the kit contains all the necessary reagents to allow immunological detection of the endothelial cell, macrophage and invasive cancer cell.
metastatic cancer, cancer diagnostic,
Patent Number / Application Number: 8642277
C-00001100
Condeelis, John S.
The patent is based on the observation that TMEM (tumor micro-environment for metastasis) is composed of CD68+ macrophage and CD31+ endothelial cells. Whether the TMEM is active (allowing tumor cell dissemination) or inactive is determined by levels of Tie2, VEGFA on the macrophages and levels of VE-Cadherin and/or ZO-1 protein on endothelial cells. It is a methods patent that discloses a method of diagnosing the presence of active or inactive TMEM sites in tumor samples. Where high levels of Tie2, VEGFA on macrophages and low levels of VE-Cadherin and/or ZO-1 on endothelial cells marks an active TMEM. The patent also outline uses of this method in determining the course of cancer treatment, efficacy of a cancer treatment, and prognosis, where the treatment is directed to inhibit TMEM. The patent also outline method of treating cancer by inhibiting or reducing tumor cell dissemination by targeting components of an active TMEM.
diagnosis, prognosis, tumor, microenvironment, metastasis
Patent Number / Application Number: 17/209,670
C-00001171
Lai, Jonathan R
The underlying invention is development of a phage display library that uses various engineered (site specific mutants) variants of glycoprotein E DIII of Dengu virus as a bait. Screening of these engineered mutants against large protein libraries led to identification of variants with better immunogenicity. These variants displayed improved immunogenicity capable of eliciting production of high-quality neutralizing antibodies. The present patent outlines nucleic acid sequence and composition of these variant forms and outlines methods for its use as vaccine in the treatment or prevention of Dengue.
Dengue virus, antibodies, page library, glycoprotein, E DIII, immunotherapy, Vaccine
Patent Number / Application Number: 10772949
C-00001378
Lai, Jonathan R
The underlying invention for this patent is the development of a phage display library that uses various engineered variants of glycoprotein E DIII of Dengu virus as a bait. The mutation in these variants are optimized for better immunogenicity by masking non-neutralizing sequences and thus called ‘resurfaced’ variants. Screening of these engineered mutants against large protein libraries led to identification of variants with better immunogenicity and capable of eliciting production of high-quality neutralizing antibodies. The current patent outlines specific nucleic acid sequence and composition of all the resurfaced Dengue virus 4 glycoprotein subunit E DIII variants (“rsD4DIIIs”) and their uses in preventing and treating Dengue virus infection. Also provided are specific resurfaced Zika virus glycoprotein subunit E DIII variants (“rsZDIIIs”) and their uses in preventing and treating Zika virus infection. Such rsD4DIIIs can be mixed with other rsD4DIIIs for broad neutralization. Besides, such rsD4DIIIs can also be be mixed with rsZDIIIs to create DENV/ZIKV multivalent vaccines. In addition, rsD4DIIIs or rsZDIIIs, or combinations thereof, can be complexed, conjugated, or coupled with nanoparticles to generate nanoparticles containing rsD4DIIIs and/or rsZDIIIs for multivalent presentation.
Dengue virus, Zika virus, antibodies, page library, glycoprotein, E DIII, vaccine
Patent Number / Application Number: PCT/US20/39403
C-00000483
Dadachova, Ekaterina
The invention harnesses the protective power of melanin (naturally occurring or chemically synthesized) against broad range of electromagnetic radiation to minimize radiotherapy induced tissue damage, namely in bone marrow. The patent outlines method of using nanoparticles comprising melanin to provide therapeutic protection in patients about to go for radiotherapy. This involves administering the patient a therapeutic protective dose of melanin nanoparticles.
tissue damage, radiation, melanin, nanoparticle
Patent Number / Application Number: 8586090
C-00000927
Jacobs, Jr., William R
The patent outlines a method of eliciting humoral immune response by delivering an attenuated form of the bacterium, Mycobacterium tuberculosis for use as a vaccine against tuberculosis. The mutant form of the bacterium is derived through deletion of the entire esx-3 region of the genome.
Vaccine, tuberculosis, TB
Patent Number / Application Number: 9637749
C-00000837
Condeelis, John S.
The patent outlines method for diagnosis of metastatic tumor, which involves determining the relative levels of phosphorylated cofilin to that of total cofilin (phosphorylated + unphosphorylated). This is achieved through co-staining of tumor samples (biopsy) with both, fluorophore tagged antibody against phosphorylated cofilin and also pan-cofilin antibody that is also tagged with a different fluorophore. Co-staining is followed by colocalization of signals through fluorescence imaging of the tumor samples and determining colocalization intensity value (IF). A tumor is considered metastatic when the IF values exceeds a predetermined threshold cutoff. The patent also outlines method of antimetastatic therapy that comprises trastuzumab or bevacizumab or both.
marker, diagnostic, metastasis, cancer, breast
Patent Number / Application Number: 11169154
C-00000540
Blanchard, John
The patent outlines a method of detecting or visualizing DNA interacting protein. These DNA interacting protein are mostly enzymes that manipulates double/single stranded DNA molecules. The technology is based on identification and purification of a pentapeptide repeat protein from bacterium, Mycobacterium tuberculosis, named MtMfpA. The MtMfpA protein is good at mimicking DNA molecule and can interact with DNA binding proteins. The patent outlines labelling these pentapeptide proteins with suitable reporter (fluorescent or otherwise) marker, radioactive nucleotides for use as assay in identifying or quantifying DNA binding proteins present in a sample.
Reporter, DNA binding protein, DNA-Protein interaction, assay,
Patent Number / Application Number: 8999894